A growing number of treatments for rare metabolic diseases, including thymidine kinase 2 deficiency (TK2d), is improving survival and quality of life, but experts say patients and families now face more difficult and deeply personal decisions that require clearer communication and shared decision-making with clinicians, according to a review published recently in Genetics in Medicine.
Over the past 30 years, therapies for inborn errors of metabolism have expanded rapidly, changing conditions that were once fatal into manageable diseases. Newborn screening programs have also grown, adding conditions such as Pompe disease, X-linked adrenoleukodystrophy and Krabbe disease since the mid-2010s. These advances mean families are often asked to make high-stakes choices earlier, sometimes before symptoms even appear.
Unlike older treatments such as diet changes or supplements, many newer options involve complex interventions like stem cell transplantation, enzyme replacement or gene therapy. These treatments can be costly, carry significant risks and may not work the same way for every patient. Insurance coverage may also be uncertain, adding financial stress to already difficult decisions.
Read more about helpful links and resources for TK2d
Shared decision-making is a process in which patients, families and clinicians work together to choose care and is essential in this setting. This approach includes explaining all options, discussing benefits and risks and understanding what matters most to the patient or family. Studies show it can improve care quality, strengthen relationships with clinicians and reduce regret about decisions later on.
For patients with TK2d, these challenges are especially relevant. Newer treatments such as nucleoside replacement therapy have shown dramatic benefits in some patients, including regained strength and developmental progress. However, responses vary and long-term outcomes remain uncertain, making treatment decisions complex and deeply individualized.
Families must also weigh the burdens of ongoing care. Many treatments are lifelong and require frequent hospital visits, time away from school or work and emotional resilience. Even when therapies help, they are often not cures, meaning patients may still face disease progression or new complications over time.
Researchers say more work is needed to understand how patients and families want information delivered and what support they need when making these decisions. They call for better tools, clearer standards and more training for clinicians in communication skills.
“Key communication skills like active listening and attending to patients’ verbal and nonverbal behaviors, expressing empathy, providing information, and asking questions are strongly emphasized in the field of genetic counseling as requisites for facilitating decision-making about genetic testing,” explained the authors of this review.
As treatment options continue to grow, improving how these conversations happen may be just as important as the therapies themselves for patients living with rare diseases such as TK2d.
Sign up here to get the latest news, perspectives, and information about TK2d sent directly to your inbox. Registration is free and only takes a minute.
